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including the product indication registered at the Thai Food and Drug 
Administration. RESULTS: Disease awareness activities were found 47 times in 
various media, of which 48.9% were on the internet, 46.8% in magazines, and 
4.3% in television programs. The main agents of information dissemination were 
government-affiliated organizations (36.7%), medical associations (19.1%), private 
hospitals (12.8%), and the pharmaceutical industry (10.7%), however, 14.9% was 
unidentifiable regarding its origin. The most common pattern of presentation 
was in review or editorial articles and the “fearing appeal” was the most typical 
presentation (59.6%). Nevertheless, 10.6% of the presented data were 
scientifically incorrect according to the evidence-based and claimed data. On 
websites, there was a connection between the sponsoring drug companies of the 
disease awareness activities through the branded logo, the theme color of the 
website, and the product packaging that matched with the specific number the 
HPV strands. Moreover, the hotline contact numbers, which were sponsored by 
the pharmaceutical industry, were also available on the websites and magazines 
for consumers to learn more about cervical cancer. CONCLUSIONS: Disease 
awareness activities are commonly found in Thailand and may pose some due 
concern regarding the misleading claims in the mass media.  
 
PCN147  
NON-TRADITIONAL SCHEMES APPROACH FOR PUBLIC MARKET ACCESS OF 
END-OF-LIFE TREATMENTS IN MEXICAN HEALTH CARE SYSTEM  
Soria-Cedillo IF1, Nevarez A2 
1Sanofi, Mexico City, Mexico, 2Public Health Care System, Mexico City, Mexico  
OBJECTIVES: To estimate budget impact in public health care system in Mexico 
with the use of cabazitaxel in the treatment of metastatic castration-resistant 
prostate cancer (MCRPC) progressing after Docetaxel regimen. METHODS: A risk 
sharing model based on clinical performance of a hypothetical cohort of MCRPC 
patients treated with cabazitaxel was evaluated. The cut-off point was 
determined by median progression free survival <PFS> (according to RECIST 
parameters) reported in TROPIC study. An exponential distribution of patients 
was simulated on a 30-week period with a cross sectional study approach 
considering clinical outcomes for every 3 weeks, a matrix of probabilities of 
transition was created. Median PFS was reported to be 2.8, a cohort of 50 patients 
was evaluated and a length of 10 cycles was assessed. The model considered a 
reimbursement to the institutions when a patient does not reach PFS reported on 
TROPIC study. Direct cost and an institutional perspective were considered. No 
discount rate was included. RESULTS: Estimated budget impact for public 
institutions to cut-off point was estimated in 861,600 USD, with a total 
investment of 1.2 million USD for the estimated number of patients reaching 10 
cycles. Reimbursement based on clinical performance was estimated in 310,200 
USD. Calculated number of patients reaching PFS clinical value was 22 patients. 
Total annual expenditure for public health care institutions of cabazitaxel usage 
under risk sharing scheme, represents 0.002% of public budget for health care 
system and 0.032% of assigned budget for therapeutic goods in main public 
health care institution in Mexico. CONCLUSIONS: Treatment of MCRPC patients 
with Cabazitaxel under a risk sharing agreement may allow patients to obtain 
clinical benefits with a low economic impact to public institutions due to the low 
number of expected patients. Novel schemes for end-of-life treatments must be 
evaluated in order to assess potential benefits for patients/institutions.  
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OBJECTIVES: Physician academic affiliations and changes in pharmaceutical 
reimbursement rates have been shown to influence physician practice patterns 
regardless of clinical guidelines, patient clinical or sociodemographic factors. We 
examined the association between urologists’ practice affiliations with medical 
schools and the utilization of gonadotropin-releasing hormone (GnRH) agonists 
before and after reductions in GnRH agonist reimbursement rates resulting from 
the 2003 United States Medicare Modernization Act (MMA). METHODS: Using the 
Surveillance, Epidemiology and End Results–Medicare linked database and the 
American Medical Association Physician Masterfile, we conducted a 
retrospective cohort study of 10,301 patients aged 66 years or older who were 
diagnosed between 2003 and 2005 with localized, low-to-intermediate grade 
prostate cancer, and the 1,577 urologists who saw them. Multilevel regression 
analyses were used to evaluate the influence of urologists’ practice affiliations 
with medical schools on primary GnRH agonist use on patients within 6 months 
of diagnosis – a treatment regimen that is at variance with clinical guidelines 
and has not been shown to improve survival or other patient –centered 
outcomes. RESULTS: Overall, 3763 (37%) patients received GnRH agonists. After 
adjusting for patient, tumor and urologist characteristics, patients who saw 
urologists with no practice affiliation with medical schools were significantly 
more likely to receive GnRH agonists (odds ratio [OR], 2.03; 95% confidence 
interval [95% CI], 1.57-2.63, p<0.0001). Compared to 2003, when the MMA went 
into effect, the odds of receiving GnRH agonists were significantly lower in 2004 
(OR, 0.76; 95% CI, 0.68-0.85, p<0.0001) and 2005 (OR, 0.51; 95% CI, 0.45-0.57, 
p<0.0001). CONCLUSIONS: Even though the overall odds of patients receiving 
unnecessary GnRH agonists decreased after the MMA reimbursement reduction, 
urologists without practice affiliations with medical schools were still 
significantly more likely to prescribe GnRH agonists; such treatment patterns are 
not consistent with patient-centered clinical guidelines and unlikely to have 
significant survival benefit.  
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We recently described treatment (tx) patterns in a representative real-world 
cohort of U.S. patients (pts) diagnosed with unresectable or metastatic 
melanoma (advanced melanoma [AM]) and found 70 unique regimens observed 
in 689 treated pts (Macahilig 2011). OBJECTIVES: To investigate if there is an 
association between tx choice and patient or practice characteristic(s) in AM. 
METHODS: Data from a random sample of 752 medical charts of newly 
diagnosed AM pts (2004-2008) from 113 US oncologists were collected. In 
analyses of the 689 pts receiving anti-cancer tx, we examined pt characteristics 
of 2 tx categories: pts receiving temozolomide (Tmz) (the most frequently 
prescribed tx) and those not receiving Tmz (“other”). Significance was defined as 
P<0.05. RESULTS: In first-line (FL) tx, pts receiving Tmz were significantly more 
likely to be male and have significantly poorer prognostic characteristics 
including ECOG PS ≥2 (41% vs. 27%); distant disease (85% vs. 68%); more 
metastatic sites (1.9 vs. 1.6); brain metastases (26% vs. 15%); elevated LDH (61% 
vs. 52%); and age ≥65 (58% vs. 41%) compared to the “other” group. FL Tmz pts 
were also significantly more likely to have public primary medical insurance 
(58% vs. 45%). There was no statistical difference in FL use of Tmz versus “other” 
tx in academic versus community practice settings or by physician melanoma 
caseload. CONCLUSIONS: The current study provides evidence that tx choice in 
AM is associated at least in part with pt characteristics.  
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OBJECTIVES: To examine factors associated with the receipt of guideline 
concordant adjuvant chemotherapy, radiation therapy, and hormonal therapy 
among women diagnosed with breast cancer. METHODS: The study population 
consisted of all women residing in a largely rural region of Southwest Georgia 
diagnosed with a first, primary, invasive early-stage (AJCC stage I, II, and IIIA) 
breast cancer from 2001-2003. Predictors of guideline-concordant adjuvant 
therapy, as recommended by the 2000 National Institutes of Health Consensus 
Development Conference Statement, were examined. Factors associated with 
receiving guideline concordance with 1) adjuvant chemotherapy; 2) adjuvant 
radiation therapy; 3) adjuvant hormonal therapy; and 4) all three adjuvant 
therapies jointly were examined using multivariable logistic regression. The 
following variables were examined: patient’s age, race, marital status, insurance 
status, socioeconomic status, urban/rural status, comorbidities, stage at 
diagnosis, grade, hormonal receptor status, treatment site, distance to treatment 
site, and type of surgery performed. Multiple imputation was used to estimate 
missing variable values. RESULTS: Overall, 41% of women were guideline 
concordant for all three adjuvant therapies jointly. Guideline concordance 
ranged from 63%-81% for the individual therapies. After adjustment, higher 
socioeconomic status was associated with guideline concordance for all three 
adjuvant therapies jointly (odds ratio [OR], 3.13, 95% CI, 1.27-7.71), and 
chemotherapy (OR, 3.13, 95% CI, 1.04-9.42) and Medicaid insurance was 
associated with guideline concordant chemotherapy (OR, 4.09; 95% CI, 1.50-
11.20). Being unmarried was associated with nonguideline concordant 
chemotherapy (OR, 0.44; 95% CI, 0.22-0.85) and radiation therapy (OR, 0.47; 95% 
CI, 0.26-0.83). Increased age predicted nonguideline concordance for all three 
adjuvant therapies jointly, chemotherapy, and radiation therapy. The results 
were robust to the use of multiple imputation. CONCLUSIONS: Patient age, 
socioeconomic status, and marital status were independently associated with 
receiving guideline concordant adjuvant therapy. Identifying and addressing 
modifiable factors that lead to non-guideline concordant treatment may reduce 
disparities in treatment and improve cancer outcomes.  
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OBJECTIVES: This study examines clinical and demographic predictors of 2ndline 
(Tx2) and subsequent-line (TxS) treatment among elderly Medicare beneficiaries 
diagnosed with metastatic colon cancer (mCC) and initiated treatment. 
METHODS: Using the SEER-Medicare dataset, beneficiaries diagnosed with mCC 
who initiated treatment from 2003-2007 were followed until death or censoring 
in 2009. Treatment lines were classified in combinations of chemotherapy and 
biologics. Logistic regression was used to predict receipt of Tx2 and TxS. 
RESULTS: Among 3266 patients diagnosed with mCC and initiated therapy, 1440 
progressed to Tx2 and 274 progressed to TxS. The strongest predictors of 
progressing to Tx2 was surgery of the primary tumor site (OR: 2.50, 95% CI: 2.16-
2.88) and marital status (OR: 1.66, 95% CI: 1.46-1.90). Older beneficiaries (>80 
years (OR: 0.20, 95% CI: 0.17-0.25) and those with 1-6 months of state buy-in (OR: 
0.31, 95%CI: 0.20-0.49) were less likely to proceed to Tx2. Surgery of the primary 
site was the biggest predictor of receipt of TxS (OR: 2.22, 95%CI: 1.62-2.99). Older 
age (>80 years (OR: 0.27, 95% CI: 0.19-0.39)) and 1-6 months of state buy-in (OR: 
0.17, 95%CI: 0.04-0.69) were the biggest predictors of not proceeding to TxS. 
When compared to the Connecticut registry area, all SEER-registry areas were 
